Frankfurt
05.08.25 | 09:43
0,303 Euro
+22,67 % +0,056
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:26 | AlzeCure Pharma: New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference | 184 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 29.07. | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 237 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 24.07. | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option | 234 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 23.07. | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed According to Preliminary Results | 220 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 21.07. | AlzeCure Pharma: AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference | 231 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 16.07. | FDA grants orphan status for AlzeCure's pain drug candidate | 3 | Pharmaceutical Business Review | ||
| 16.07. | AlzeCure Pharma: AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue | 235 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 15.07. | AlzeCure Pharma: AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA | 264 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.07. | The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares | 287 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - At an extraordinary general meeting in AlzeCure Pharma AB on July 2, 2025, the shareholders decided to approve... ► Artikel lesen | |
| 02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 188 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 17.06. | AlzeCure Pharma: AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue | 319 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 16.06. | Notice To Extraordinary General Meeting In Alzecure Pharma AB | 290 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB are hereby summoned to an extraordinary general meeting to be held on... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma: AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million | 363 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 12.06. | AlzeCure Pharma: AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease | 384 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 12, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 04.06. | AlzeCure Pharma to present at Redeye Investor Forum on June 11 | 293 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 4, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 03.06. | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10 | 335 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 3, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 14.05. | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2025 | 386 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 14, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 14 May 2025, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2025 | 396 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - March 2025 | 262 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The... ► Artikel lesen | |
| 09.04. | Notice to Annual General Meeting in AlzeCure Pharma AB | 441 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 9, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 324,30 | -20,49 % | Studie eingestellt: Vertex Pharmaceuticals crasht trotz starker Quartalszahlen! | Die Aktie von Vertex Pharmaceuticals steht am Dienstag vor empfindlichen Verlusten. Starke Quartalszahlen werden von einer eingestellten Studie überschattet. Vertex Pharmaceuticals: Einer der konstantesten... ► Artikel lesen | |
| VIATRIS | 7,726 | -0,10 % | Aktienmarkt: Kurs der Aktie von Viatris im Plus (7,75006 €) | Das Wertpapier von Viatris notiert heute ein wenig fester. Das Papier kostete zuletzt 8,97 US-Dollar. Für der Anteilsschein von Viatris steht gegenwärtig ein Preisanstieg 1,82 Prozent zu Buche. Das... ► Artikel lesen | |
| ALTIMMUNE | 3,186 | +3,07 % | Altimmune, Inc: Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 | ||
| OPKO HEALTH | 1,043 | -4,63 % | OPKO Health outlines $640M-$660M 2025 revenue target as BioReference sale and pipeline advances drive profitability push | ||
| JAGUAR HEALTH | 2,240 | +3,70 % | Jaguar Health, Inc.: Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,406 | +2,48 % | SELLAS Life Sciences Group, Inc.: SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study | The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 10,100 | +2,00 % | Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration | ||
| KIORA PHARMACEUTICALS | 2,550 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease | Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment... ► Artikel lesen | |
| LIPOCINE | 3,130 | -2,80 % | Lipocine Inc.: Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 | SALT LAKE CITY, Aug. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,318 | -1,97 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and ... | - Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved... ► Artikel lesen | |
| PHOTOCURE | 5,270 | +0,38 % | Photocure ASA: Results for the second quarter of 2025 | OSLO, Norway, July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million)... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 25,250 | +1,41 % | Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy | Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy Paris, July 1st, 2025 Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME... ► Artikel lesen | |
| MEDICURE | 0,655 | 0,00 % | Medicure, Inc.: Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy | WINNIPEG, MB / ACCESS Newswire / June 17, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 27,725 | +0,84 % | Achtung bei BioNTech! Bayer, Formycon und Vidac Pharma Aktie drehen auf! | Während bei BioNTech derzeit jeder auf die Quartalszahlen am 4. August zu warten scheint, drehen andere Aktien auf. Bei Vidac Pharma halten Analysten eine Vervielfachung für möglich, außerdem gibt es... ► Artikel lesen | |
| MERCK KGAA | 107,90 | -0,28 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA vor Zahlen auf "Overweight" mit einem Kursziel von 155 Euro belassen. Richard Vosser verglich in einer am Mittwoch... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +22,67 % bei einem Aktienkurs von 0,303 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.